Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next‑Generation RDCs in Precision Oncology

Fineline Cube Dec 29, 2025
Company Deals

Kleos Health and BioInno Bioscience Forge China Partnership for Exosome Drugs in Orthopedics

Fineline Cube Dec 29, 2025
Company Deals

Hybio Pharmaceutical, Dr. Reddy’s Forge Peptide API Partnership

Fineline Cube Dec 29, 2025
Company Deals

Shionogi Acquires RADICAVA ALS Business for $2.5 Billion from Tanabe Pharma

Fineline Cube Dec 23, 2025
Company Deals

Coherent Biopharma Licenses PDC CBP-1018 to MultiValent in $2 Billion Prostate Cancer Deal

Fineline Cube Dec 23, 2025
Company Policy / Regulatory

NDRC Expands Foreign Investment in Healthcare with 2025 Catalogue

Fineline Cube Dec 29, 2025
Company Drug

Sino Biopharmaceutical’s TQH3906 Achieves 90% PASI 75 Response in Phase 2 Psoriasis Trial

Fineline Cube Dec 29, 2025
Company Drug

AstraZeneca and Ionis’ Eplontersen Wins China Approval for ATTRv-PN as First Gene-Silencing Therapy

Fineline Cube Dec 29, 2025
Company Drug

Juventas Cell Therapy’s CNCT19 Receives FDA IND Approval for r/r B-ALL Treatment

Fineline Cube Mar 14, 2023

China-based Juventas Cell Therapy Ltd’s chimeric antigen receptor (CAR) T-cell therapy, CNCT19 (Inaticabtagene Autoleucel), has...

Company Drug

Bio-Thera Solutions Initiates First Patient Dosing in Phase I Study of BAT8007

Fineline Cube Mar 14, 2023

China-based Bio-Thera Solutions, Ltd. (SHA: 688177) has announced the first patient dosing in a multi-center,...

Company Drug

Antengene to Begin Phase I Clinical Study of ATG-022 for Advanced Solid Tumors

Fineline Cube Mar 14, 2023

China-based Antengene Corporation Ltd (HKG: 6996) is poised to commence a Phase I clinical study...

Company Drug

Guangdong Zhongsheng’s RAY1225 Receives NMPA Approval for Clinical Study

Fineline Cube Mar 14, 2023

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced that it has received approval...

Company Deals

AnnJi Pharma Signs USD 250 Million Licensing Deal with Avenue Therapeutics for Kennedy’s Disease Drug

Fineline Cube Mar 14, 2023

Taiwan-based AnnJi Pharmaceutical Co., Ltd has announced the signing of a licensing agreement with US...

Company Drug

Vcanbio’s VUM02 Gains CDE Review for Liver Failure and ARDS Clinical Trials

Fineline Cube Mar 14, 2023

Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that two additional clinical...

Company Drug

Luye Pharma’s Biosimilar BA9101 Completes Phase III Study Enrollment with Ocumension

Fineline Cube Mar 14, 2023

China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary, Shandong Boan Biotechnology Co., Ltd, has completed...

Company Deals

Immunophage Biotech Raises RMB 200 Million in Series B1 Financing for Clinical Trials

Fineline Cube Mar 14, 2023

Nanjing-based Immunophage Biotech Co., Ltd reportedly raised close to RMB 200 million (USD 29.1 million)...

Company Drug

Akeso Biopharma Enrolls First Subject in Phase III Study of Cadonilimab for Gastric Cancer

Fineline Cube Mar 14, 2023

China-based Akeso Biopharma (HKG: 9926) has announced the enrollment of the first subject in a...

Company Drug

CSPC Pharmaceutical’s PD-1 Monoclonal Antibody Enlangsubai Completes NMPA Market Approval Filing

Fineline Cube Mar 14, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced the completion of a market approval...

Deals R&D

Pasteur Institute Suspends Joint Venture with Chinese Academy of Sciences

Fineline Cube Mar 14, 2023

France’s Pasteur Institute has announced its decision to suspend its joint-venture (JV) partnership with the...

Company Medical Device

Boston Scientific Launches REPLACE Study for FARAPULSE PFA System in China

Fineline Cube Mar 14, 2023

US-based medical technology major Boston Scientific Corporation (NYSE: BSX) has announced the initiation of the...

Company Drug

Chipscreen’s Epidaza Receives TFDA Approval for Breast Cancer Treatment in Taiwan

Fineline Cube Mar 13, 2023

Shenzhen Chipscreen Pharmaceutical Co., Ltd’s partner, GNT Biotech & Medicals Corporation, has announced that it...

Company Deals

Silicon Valley Bank Collapse Impacts Tech and Biotech Sectors Globally

Fineline Cube Mar 13, 2023

The tech and biotech sectors are grappling with the implications of the collapse of US-based...

Company Deals

Allorion Therapeutics Raises USD 50 Million in Series B Financing to Advance Drug Development

Fineline Cube Mar 13, 2023

Allorion Therapeutics, a next-generation precision medicine small molecule drug developer based in Guangzhou, reportedly raised...

Company Deals

XtalPi and Chia Tai Tianqing Achieve Phase II Milestone in Cancer Drug Development

Fineline Cube Mar 13, 2023

Sino-US artificial intelligence (AI) firm XtalPi Inc. has partnered with China’s Chia Tai Tianqing to...

Company Deals

Overland Pharmaceuticals Partners with GoBroad Healthcare to Strengthen Cell Therapy Research

Fineline Cube Mar 13, 2023

China-based firm Overland Pharmaceuticals has entered into a strategic partnership with GoBroad Healthcare Group to...

Company Drug

Haihe Pharmaceutical Initiates Global Phase I Clinical Study for BET-BD2 Inhibitor HH3806

Fineline Cube Mar 13, 2023

Shanghai Haihe Pharmaceutical Co., Ltd has announced the first patient dosing of a global multi-center...

Company Drug

CanSino Biologics Initiates Phase Ib Study for Innovative Protein-Based Pneumococcal Vaccine

Fineline Cube Mar 13, 2023

China-based vaccines specialist CanSino Biologics Inc. has announced the initiation and first subject enrollment of...

Company Deals

Zenshine Pharmaceuticals Raises RMB 100 Million in Series B Financing for Drug Development

Fineline Cube Mar 13, 2023

China-based small molecule drug developer Nanjing Zenshine Pharmaceuticals Co., Ltd reportedly raised over RMB 100...

Posts pagination

1 … 487 488 489 … 602

Recent updates

  • Sino Biopharmaceutical’s TQH3906 Achieves 90% PASI 75 Response in Phase 2 Psoriasis Trial
  • HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next‑Generation RDCs in Precision Oncology
  • Kleos Health and BioInno Bioscience Forge China Partnership for Exosome Drugs in Orthopedics
  • AstraZeneca and Ionis’ Eplontersen Wins China Approval for ATTRv-PN as First Gene-Silencing Therapy
  • AstraZeneca Secures NMPA Approval for Fasenra in EGPA, Demonstrating Superior Steroid-Sparing Effect
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Sino Biopharmaceutical’s TQH3906 Achieves 90% PASI 75 Response in Phase 2 Psoriasis Trial

Company Deals

HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next‑Generation RDCs in Precision Oncology

Company Deals

Kleos Health and BioInno Bioscience Forge China Partnership for Exosome Drugs in Orthopedics

Company Drug

AstraZeneca and Ionis’ Eplontersen Wins China Approval for ATTRv-PN as First Gene-Silencing Therapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.